Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)

Tsutomu Takeuchi; Yoshiya Tanaka; Sakae Tanaka; Atsushi Kawakami; Yeong Wook Song; Yi Hsing Chen; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko; Yoshihiro Nakashima; Teruaki Shiomi; Emi Yamada

doi:10.1186/s13075-020-02247-3

Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)

Tsutomu Takeuchi^*, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong Wook Song, Yi Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi, Emi Yamada

^*此作品的通信作者

醫學系內科學科

研究成果: Comment/debate

摘要

Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

原文	English
文章編號	155
期刊	Arthritis Research and Therapy
卷	22
發行號	1
DOIs	https://doi.org/10.1186/s13075-020-02247-3
出版狀態	Published - 23 6月 2020

存取文件

10.1186/s13075-020-02247-3

其它文件與鏈接

Link to publication in Scopus

指紋

深入研究「Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)」主題。共同形成了獨特的指紋。

引用此

Takeuchi, T., Tanaka, Y., Tanaka, S., Kawakami, A., Song, Y. W., Chen, Y. H., Rokuda, M., Izutsu, H., Ushijima, S., Kaneko, Y., Nakashima, Y., Shiomi, T., & Yamada, E. (2020). Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). Arthritis Research and Therapy, 22(1), 文章 155. https://doi.org/10.1186/s13075-020-02247-3

Takeuchi, Tsutomu ; Tanaka, Yoshiya ; Tanaka, Sakae 等. / Erratum : Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). 於: Arthritis Research and Therapy. 2020 ; 卷 22, 編號 1.

@article{f9ebbefe24e441af8fae6b72422f146e,

title = "Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)",

abstract = "Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.",

author = "Tsutomu Takeuchi and Yoshiya Tanaka and Sakae Tanaka and Atsushi Kawakami and Song, {Yeong Wook} and Chen, {Yi Hsing} and Mitsuhiro Rokuda and Hiroyuki Izutsu and Satoshi Ushijima and Yuichiro Kaneko and Yoshihiro Nakashima and Teruaki Shiomi and Emi Yamada",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = jun,

day = "23",

doi = "10.1186/s13075-020-02247-3",

language = "English",

volume = "22",

journal = "Arthritis Research and Therapy",

issn = "1478-6354",

publisher = "BioMed Central Ltd.",

number = "1",

}

Takeuchi, T, Tanaka, Y, Tanaka, S, Kawakami, A, Song, YW, Chen, YH, Rokuda, M, Izutsu, H, Ushijima, S, Kaneko, Y, Nakashima, Y, Shiomi, T & Yamada, E 2020, 'Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)', Arthritis Research and Therapy, 卷 22, 編號 1, 155. https://doi.org/10.1186/s13075-020-02247-3

Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). / Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae 等.
於: Arthritis Research and Therapy, 卷 22, 編號 1, 155, 23.06.2020.

研究成果: Comment/debate

TY - JOUR

T1 - Erratum

T2 - Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2)

AU - Takeuchi, Tsutomu

AU - Tanaka, Yoshiya

AU - Tanaka, Sakae

AU - Kawakami, Atsushi

AU - Song, Yeong Wook

AU - Chen, Yi Hsing

AU - Rokuda, Mitsuhiro

AU - Izutsu, Hiroyuki

AU - Ushijima, Satoshi

AU - Kaneko, Yuichiro

AU - Nakashima, Yoshihiro

AU - Shiomi, Teruaki

AU - Yamada, Emi

PY - 2020/6/23

Y1 - 2020/6/23

N2 - Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

AB - Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

UR - http://www.scopus.com/inward/record.url?scp=85087003304&partnerID=8YFLogxK

U2 - 10.1186/s13075-020-02247-3

DO - 10.1186/s13075-020-02247-3

M3 - Comment/debate

C2 - 32576246

AN - SCOPUS:85087003304

SN - 1478-6354

VL - 22

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

IS - 1

M1 - 155

ER -

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song YW, Chen YH 等. Erratum: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (Arthritis Research and Therapy (2020) 22 (47) DOI: 10.1186/s13075-020-2125-2). Arthritis Research and Therapy. 2020 6月 23;22(1):155. doi: 10.1186/s13075-020-02247-3